Transsphenoidal selective adenomectomy is the most efficient primary t
reatment for acromegaly. However, management of persistent or recurren
t disease remains controversial. The objective of the present study wa
s to evaluate the early and long-term efficacy and safety of a second
transsphenoidal surgery performed in those cases. The results of a ret
rospective study of 16 patients undergoing reoperation by the senior a
uthor (J.H.) between 1970 and 1991 are reported. Reoperation was perfo
rmed for persistent or progressive acromegaly in 11 patients, visual i
mpairment in four, and disease recurrence in one. Normalization of gro
wth hormone (GH) was defined as a basal GH level of less than 5 mu g/L
and suppression to less than 2 mu g/L during the oral glucose toleran
ce test. Long-term follow-up data were available in 15 patients. The s
econd transsphenoidal surgery induced a greater than 50% decrease of G
H level in 11 patients. Three (19%) of 16 patients were cured accordin
g to the authors' criteria and remained so after 2, 7, and 20 years. T
wo more patients had a postoperative basal GH level of less than 5 mu
g/L but incomplete suppression during the oral glucose tolerance test.
Thus, a total of five patients (31%) achieved a basal GH of less than
5 mu g/L. One other patient who had no initial improvement after the
second transsphenoidal surgery had spontaneous normalization of his GH
level after 13 years. The following complications of the second surge
ry occurred in three patients: one subarachnoid hemorrhage, two new vi
sual field defects, one cranial nerve palsy, and one meningitis. Moreo
ver, 10 patients (62.5%) developed one or more new pituitary hormone d
eficiencies. In conclusion, reoperation for persistent or recurrent ac
romegaly has low success and high complication rates. According to the
authors' experience, this procedure should be reserved for patients u
nresponsive to other forms of therapy or with progressive visual impai
rment despite medical therapy.